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CH-4002 Basel, SwitzerlandAbstract—In adult macaquemonkeys subjected to an incom-
plete spinal cord injury (SCI), corticospinal (CS) ﬁbers are
rarely observed to grow in the lesion territory. This situation
is little aﬀected by the application of an anti-Nogo-A antibody
which otherwise fosters the growth of CS ﬁbers rostrally and
caudally to the lesion. However, when using the Sternberger
monoclonal-incorporated antibody 32 (SMI-32), a marker
detecting a non-phosphorylated neuroﬁlament epitope,
numerous SMI-32-positive (+) ﬁbers were observed in the
spinal lesion territory of 18 adult macaque monkeys; eight
of these animals had received a control antibody infusion
intrathecally for 1 month after the injury, ﬁve animals an
anti-Nogo-A antibody, and ﬁve animals received an anti-
Nogo-A antibody together with brain-derived neurotrophic
factor (BDNF). Theseﬁbers occupied thewhole dorso-ventral
axis of the lesion site with a tendency to accumulate on the
ventral side, and their trajectories were erratic. Most of these
ﬁbers (about 87%) were larger than 1.3 lm and densely SMI-
32 (+) stained. In the undamagedspinal tissue,motoneurons
form the only large population of SMI-32 (+) neurons which
are densely stained and have large diameter axons. These
data therefore suggest that a sizeable proportion of the ﬁbers
seen in the lesion territory originate from motoneurons,
althoughﬁbers of other origins could also contribute. Neither
the presence of the antibody neutralizing Nogo-A alone, nor
the presence of the antibody neutralizing Nogo-A combined
with BDNF inﬂuenced the number or the length of the
SMI-32 (+) ﬁbers in the spinal lesion area. In summary, our
data show that after a spinal cord lesion in adult monkeys,0306-4522  2012 IBRO. Published by Elsevier Ltd.
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INTRODUCTION
In the adult central nervous system (CNS) of mammals,
axotomized nerve ﬁbers fail to regenerate over long
distances. Among the factors contributing to this failure,
the development of a scar tissue at the lesion site leads
to the formation of an environment hostile to nerve ﬁbers’
regrowth and acting as a barrier against axonal
regeneration into and across the lesion territory. Indeed,
the scar tissue contains various neurite growth-inhibiting
factors produced by cells such as microglial cells,
meningeal cells, astrocytes or oligodendrocytes (Reier
et al., 1983; Schwab and Bartholdi, 1996; Schwab, 2002;
David and Lacroix, 2003). These last years, several
growth-inhibiting molecules expressed in the scar tissue
were identiﬁed such as the chondroitin sulfate
proteoglycans (CSPGs), tenascin-c or semaphorins
(Rudge and Silver, 1990; McKeon et al., 1991; Davies
et al., 1997, 1999; Fawcett and Asher, 1999; Pasterkamp
and Verhaagen, 2001). Nogo-A present in CNS myelin
and oligodendrocytes inhibits the regeneration of spinal-
lesioned axons (Schwab, 2004, 2010). In rodents, the
application at the level of the spinal cord of an antibody
neutralizing Nogo-A promotes both corticospinal (CS)
ﬁbers regeneration and functional recovery (Schnell and
Schwab, 1990; Thallmair et al., 1998; Schwab, 2004;
Liebscher et al., 2005; Maier et al., 2009). Experiments
conducted on primates lead to similar results (Freund
et al., 2006, 2007, 2009). In particular, these experiments
have shown that in anti-Nogo-A antibody-treated
monkeys, CS ﬁbers sprout and regenerate rostrally,
around and caudally to the spinal lesion (Fouad et al.,
2004; Freund et al., 2006, 2007). However, in these
animals, CS ﬁbers were only exceptionally observed
inside the lesion territory. Nevertheless, it remains
possible that following spinal cord injury (SCI), neurons
distinct from CS neurons show an ability to regenerate
and to grow in or even through the scar tissue.
Neuroﬁlaments constitute the main structural element
of the neuronal cytoskeleton and the presence in neurons
of non-phosphorylated forms of neuroﬁlaments can be
shown using the Sternberger monoclonal-incorporated
Open access under CC BY-NC-ND license.-ND license.
Table 1. Individual characteristics and summary data for all animals included in the study
Name Mk-CB Mk-CBo Mk-CC Mk-CGa Mk-CG Mk-CH Mk-CP MK-CS
1,2,3,4 – 1,3 – 1,2,3,4 1,2,3,4 1,2,3 1,3,4
Species Fasc. Fasc. Mul. Fasc. Fasc. Fasc. Fasc. Mul.
Sex $ # # # # # $ #
mAB received Control Control Control Control Control Control Control Control
Amount mAB (mg) 80 14 14.8 14 36 36 14.8 14.8
BDNF treatment No No No No No No No No
Amount BDNF (mg) – – – – – – – –
BDA transport time (days) 78 99 21 87 70 62 78 35
Lesion to BDA injection delay (days) 147 93 86 69 70 76 81 167
Hemisection extent (%) 75 93 38 73 51 90 45 63
Functional recovery (%) 78 99 83 100 90 53 83 22
Age of the animal at the sacriﬁce (years) 5 4 4 4 4 4 6.9 4.5
Nb. ﬁbers with Ø < 1.3 lm 266 190 64 83 34 232 143 24
Nb. ﬁbers with Ø > 1.3 lm 780 884 305 989 404 2307 657 158
Nb. ﬁbers in the lesion territory 1046 1074 369 1072 438 2539 800 182
Cumulative length for ﬁbers with Ø < 1.3 lm 13.6 21.6 4.5 6.0 3.1 21.9 20.5 2.7
Cumulative length for ﬁbers with Ø > 1.3 lm 63.0 94.0 27.6 72.6 31.2 178.9 86.5 18.9
Cumulative length for all ﬁbers in the lesion 76.5 115.6 32.0 78.6 34.3 200.8 107.0 21.6
Volume of BDA injection (in ll) 20 34.5 24 20 24
Nb. of BDA injection sites 10 21 12 10 12
Name Mk-AC Mk-AF Mk-AG Mk-AK Mk-AM Mk-ABB Mk-ABMa Mk-ABMx Mk-ABP Mk-ABS
1,2,3,4 1,3,4 2,4 3 1,2,3,4 – – – – –
Species Fasc. Mul. Fasc. Fasc. Fasc. Fasc. Fasc. Fasc. Fasc. Fasc.
Sex # # # # # # # # # #
mAB received hNogoA 11C7 hNogoA hNogoA hNogoA hNogoA hNogoA hNogoA hNogoA hNogoA
Amount mAB (mg) 36 14.8 14.6 36 36 36 36 36 36 36
BDNF treatment No No No No No Yes Yes Yes Yes Yes
Amount BDNF (mg) – – – – – 1.4 1.4 1.4 1.4 1.4
BDA transport time (days) 64 71 70 62 69 76 65 79 69 62
Lesion to BDA injection delay (days) 71 187 42 90 69 91 84 179 111 111
Hemisection extent (%) 85 56 78 86 80 83 94 95 77 93
Functional recovery (%) 100 57 100 100 96 93 68 78 70 66
Age of the animal at the sacriﬁce (years) 4 6.25 3.5 3.5 4 5 4 5 4.5 4.5
Nb. ﬁbers with Ø < 1.3 lm 73 47 46 301 145 32 49 124 705 328
Nb. ﬁbers with Ø > 1.3 lm 821 82 94 505 1607 526 918 1017 1199 953
Nb. ﬁbers in the lesion territory 894 129 140 806 1752 558 967 1141 1904 1281
Cumulative length for ﬁbers with Ø < 1.3 lm 6.6 4.7 3.2 26.2 17.5 4.6 3.1 12.3 41.2 23.6
Cumulative length for ﬁbers with Ø > 1.3 lm 59.9 4.3 8.3 75.9 131.3 56.3 77.2 93.4 88.0 67.9
Cumulative length for all ﬁbers in the lesion 66.5 9.0 11.5 102.1 148.8 60.9 80.4 105.7 129.2 91.5
Volume of BDA injection (in ll) 20 28 19 26 28.5 34.5
Nb. of injection sites 10 15 10 12 19 27
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M.-L. Beaud et al. / Neuroscience 227 (2012) 271–282 273antibody 32 (SMI-32) (Sternberger and Sternberger, 1983;
Lee et al., 1988). Inside the spinal cord, motoneurons
present a strong SMI-32 immunoreactivity (Tsang et al.,
2000). The goal of the present study was to investigate,
using the SMI-32 antibody whether neurites can cross the
scar tissue and colonize the lesion site and whether the
anti-Nogo-A antibody treatment alone or combined with
brain-derived neurotrophic factor (BDNF) can inﬂuence
such regenerating nerve ﬁbers.
EXPERIMENTAL PROCEDURES
Animals
Tissue material derived from 18 young adult macaques
(3.5–6.9 years old; weight ranging from 3.0 to 5.0 kg), subjected
to an incomplete spinal cord hemisection performed at cervical
level C7/C8, was analyzed histologically. These animals were
part of several studies on the consequences of anti-Nogo-A
antibody treatment on the regeneration of CS axons as well as
on behavioral recovery after cervical cord injury. Separate data
from 10 of these animals have appeared in previous
reports (Freund et al., 2006, 2007, 2009; Beaud et al., 2008;
Wannier-Morino et al., 2008). Surgery and care of the animals
were in conformity to the Guide for the Care and Use of
Laboratory Animals (ISBN 0-309-05377-3; 1996) and authorized
by local Swiss veterinary authorities. The housing conditions as
well as the surgical procedures were reported in detail in earlier
reports (Schmidlin et al., 2004, 2005; Freund et al., 2006, 2007,
2009). The experimental protocol can be summarized as
follows. In a ﬁrst stage, the animals were trained to perform
behavioral (manual dexterity) tasks until they reached a stable
behavioral score (pre-lesion plateau). In the second stage, an
incomplete unilateral cervical cord hemisection was performed
and the tip of a catheter attached to an osmotic pump was
inserted intrathecally at the lesion site. A group of eight animals
received a control antibody (14–80 mg/animal), a second group
of ﬁve animals received an anti-Nogo-A antibody treatment
(total: 14.6–36 mg/animal), and a last group of ﬁve animals
received a combined treatment of anti-Nogo-A antibody (36 mg/
animal) and BDNF (1.4 mg/animal). The treatments were
initiated immediately after the lesion and lasted 1 month.
In a third stage, starting immediately after the lesion, each
animal was assessed behaviorally until it reached a stable
score (post-lesion plateau). In the fourth stage, the anterograde
tracer biotin dextran amine (BDA) was injected into the
contralesional motor cortex. In some animals, a dextran–
ﬂuorescein tracer was injected in the ipsilesional motor cortex.
After about 2 months, delay to allow anterograde transport of
the tracers, the animals were sacriﬁced. In this report, the code
identifying each animal is built in two parts: the ﬁrst letters of
the code indicate the treatment given (Mk-C for the control
antibody treatment, Mk-A for the anti-Nogo-A antibody
treatment, Mk-AB for the combined anti-Nogo-A antibody/
BDNF treatment) and the additional letter(s) individuate the
corresponding animal. The experimenter was blind as to the
treatment of the animals and a diﬀerent identiﬁcation code was
used during the whole duration of the experimental period.
The ﬁnal identiﬁcation code was set after the sacriﬁce of the
animals when the lesion was reconstructed and some of the
behavioral and anatomical data analyzed.
Histology (BDA/SMI-32/dextran–ﬂuorescein staining)
When the animals had reached a stable behavioral score post-
lesion, approximately 100 days following the lesion, the BDA
tracer was injected unilaterally in the contralesional motor
cortex (hand territory) using Hamilton syringes (Table 1). After
274 M.-L. Beaud et al. / Neuroscience 227 (2012) 271–282transport time (Table 1), the animals were sacriﬁced as follows.
First, the monkeys were sedated with ketamine. Then, they
received a lethal injection of sodium pentobarbital (90 mg/kg)
intraperitoneally. They were then perfused transcardially with
0.4 l of saline (0.9%), followed by 3 l of a ﬁxative solution (4%
of paraformaldehyde in 0.1 M of phosphate buﬀer, pH 7.6). The
perfusion continued subsequently with two solutions of similar
ﬁxative containing sucrose of increasing concentrations (10%,
20%) and ended with a 30% sucrose solution in phosphate
buﬀer (pH 7.6). At the end of the perfusion, the entire CNS was
isolated and placed during few days in a 30% solution of
sucrose in phosphate buﬀer (pH 7.6) for cryoprotection. A
spinal cord segment (C3-T4) comprising the lesion was cut
parasagittally in either three or ﬁve series of respectively 50 or
30-lm sections and processed to visualize either BDA or SMI-
32 staining. More rostral and caudal spinal cord segments were
cut in 50-lm-thick coronal sections and also collected in series.
The SMI-32 staining was carried out according to the following
protocol: ﬁrst, to remove the endogenous peroxidase activity,
the free-ﬂoating sections were preincubated during 10 min in
1.5% H2O2 in phosphate-buﬀered saline (PBS; pH 7.2) and
incubated overnight at 4 C in SMI-32 monoclonal antibody
(Sigma, dilution 1:3000) in addition to 2% normal horse serum
and 0.2% Triton X-100; then the sections were rinsed several
times in PBS. After that, the sections were rinsed several times
again and incubated in a biotinylated secondary antibody
(1:200, Vector Burlingame, CA, USA) during 30–60 min at room
temperature. Finally, the sections were stained with the avidin–
biotin complex (ABC) immunoperoxidase method (Vectastain
Elite kits, Vector, Burlingame, CA, USA). The reaction was
visualized with 3,30-diaminobenzidine tetrahydrochloride (DAB
0.05%) as the chromogen, diluted in Tris–saline with 0.001%
H2O2. The sections were then washed, mounted on gelatin-
coated slides, dehydrated, and coverslipped. In the present
investigation, the number and the cumulative length of the SMI-
32 (+) ﬁbers visible in the lesion site were assessed at 400
magniﬁcation using a light microscope (Olympus) and the
software Neurolucida (MicroBrightField, Williston, VT, USA).
The sections analyzed in the present study were used
previously in some of the monkeys to reconstruct the location
and the extent of the cervical lesion in previous reports
(Schmidlin et al., 2004; Wannier et al., 2005; Freund et al.,
2009). Finally, for nine animals (ﬁve control antibody-treated;
one anti-Nogo-A antibody-treated and three anti-Nogo-A
antibody/BDNF-treated) the SMI-32-positive ﬁbers’ thickness
(diameter) was measured.Treatments
Three diﬀerent puriﬁed IgG antibodies (concentrated to
3.7–10 mg/ml in PBS) were used in the present study. The
antibodies were delivered intrathecally at the site of the lesion
via a catheter attached to an osmotic pump (Alzet 2M2 or
2M4). The pumps were placed in the back of the animal and
the treatment started within minutes following the spinal cord
lesion. After about 30 days, the pumps were removed. The
control antibody corresponds to a mouse monoclonal antibody
directed against wheat auxin (AMS Biotechnology, Oxon/UK)
and it was administrated up to a total amount of 14–36 mg in
eight animals. The anti-Nogo-A antibody (14–36 mg) delivered
during 4 weeks to four animals (Table 1) corresponded to a
mAB hNogo-A monoclonal antibody which recognizes a deﬁned
Nogo-A region of the human Nogo-A sequence. The monkey
Mk-AF (Table 1) received a monoclonal antibody (11C7; 14 mg
in 4 weeks) directed against a rat Nogo-A sequence of 18
amino acids (aa623–640) which builds a strong inhibitory
region of the Nogo-A protein. On Western blots, both anti-
Nogo-A antibodies can identify in a monospeciﬁc manner the
primate-Nogo-A protein (Oertle et al., 2003; Weinmann et al.,
2006). The question of whether the two types of anti-Nogo-Aantibodies present a diﬀerence in eﬃcacy was not addressed
in the present study because only one animal was treated
with the 11C7 type of anti-Nogo-A antibody. Five animals
(Mk-ABBo, Mk-ABMa, Mk-ABMx, Mk-ABP and Mk-ABS) have
received the anti-Nogo-A antibody treatment (36 mg in
4 weeks), combined to 1.4 mg of the neurotrophic factor BDNF
(Peprotech, UK) diluted in artiﬁcial CSF (150 mM Na, 3 mM K,
1.4 mM Ca, 0.8 mM Mg, 1 mM P, 155 mM Cl) and delivered
intrathecally from a second similar osmotic pump caudally to
the lesion site during the same period of 4 weeks (Table 1).
For statistics, we compared the diameter distribution of ﬁbers
in the lesion territory with that of motoneurons’ axons using the
Student’s t-test. For assessing whether the number or the
length of the ﬁbers inside the lesion site were aﬀected in one of
the groups that received growth-promoting substances, we
performed multivariate nonparametric analysis using the R
program (R Development Core Team, 2008) with the MNM
package (Klaus Nordhausen et al., 2009). This approach uses
a nonparametric multivariate rank test (Oja and Randles, 2004)
and is equivalent to the approach we used in a previous report
(Freund et al., 2009).RESULTS
Cervical cord lesion
All the animals were subjected to an incomplete spinal
cord hemisection at the level of the transition between
the segments C7 and C8. The lesions sites were clearly
identiﬁable in all animals and reconstructed from the
histological sections. Their relative size was determined
as a proportion (in percent) of the extent of the hemi-
cord cross-sectional surface (Table 1) and was always
clearly identiﬁable. The lesion extent ranged between
38% and 95% of the hemicord surface. In nearly all
monkeys, the lesion completely interrupted the
dorsolateral funiculus, spared large portions of the
dorsal columns and spread in the ventral quadrant. Two
representative histological reconstructions of the spinal
cord lesion are shown in Fig. 2.Which spinal elements are labeled by SMI-32
staining?
The SMI-32 antibody recognizes an epitope on non-
phosphorylated neuroﬁlaments, which is only expressed
by speciﬁc categories of neurons (Sternberger and
Sternberger, 1983; Campbell and Morrison, 1989). We
identiﬁed and analyzed thin and large SMI-32 (+) ﬁbers
in all animals, without any particular individual diﬀerence
of distribution in the lesion site. Cross sections from
intact spinal cord tissue segments located rostrally to
the spinal cord lesion and stained for SMI-32 revealed
that among spinal neurons, motoneurons were the most
heavily stained (Fig. 1A, F, white arrowheads). Other
SMI-32-stained neurons are scattered across the entire
gray matter but only few of them were as heavily
stained as motoneurons (Fig. 1E, white arrowhead). In
the white matter, lightly stained axons were often
visible, as for instance in the dorsal funiculus (Fig. 1B),
in the dorsal root entry zone (Fig. 1C) or in the
dorsolateral funiculus (Fig. 1D), whereas heavily stained
axons were rare, with the exception of axons present in
the spino-cervical tract (Fig. 1C). Motoneuronal axons in
Fig. 1. Distribution of SMI-32-stained elements inside the spinal cord. (A) SMI-32-stained coronal section from a level rostral to the cervical lesion.
The gray matter is easily distinguishable from the white matter and presents numerous sites with darkly stained elements. In particular, in the ventral
gray matter, strongly stained pools of motoneurons are well recognizable (white arrowheads; F). In the white matter, apart from bundles of ﬁber
spreading in the plane of the section (white arrows), no conspicuous elements are seen. (B) At higher magniﬁcations, lightly stained SMI-32 (+)
ﬁbers can be seen in the left portion of this microphotograph in the dorsal columns. This portion is in the region containing ascending axons which
have not been sectioned by the lesion. On the right of the microphotograph, which corresponds to a region where axons have degenerated after the
lesion, no such staining is found. (C) Numerous well-stained SMI-32 (+) ﬁbers are present in the posterior spinocerebellar tract. (D) Moderately
stained SMI-32 (+) ﬁbers are present in the dorsolateral funiculus. (E) The gray matter is ﬁlled with a ﬁne mesh of SMI-32 (+) neuropile
components in which few large (white arrowhead) and frequent small (white arrows) positively stained cell bodies are disseminated. (F) The
motoneurons pools (white arrowheads) build the only sites where numerous heavily stained SMI-32 (+) neurons are grouped. Scale bars = (A)
500 lm and (B–F) 100 lm.
M.-L. Beaud et al. / Neuroscience 227 (2012) 271–282 275the white matter were also heavily stained (Fig. 1A, F,
white arrows).SMI-32-stained ﬁbers in the lesion territory
The number of SMI-32-stained ﬁbers in the lesion territory
varied from a total of 129 counted ﬁbers in Mk-AF to a
maximal value of 2539 ﬁbers in Mk-CH (Table 1). Fig. 2
depicts two SMI-32-stained longitudinal sections of the
spinal cord at the lesion site. In the ﬁrst section, the
lesion extends through the entire dorso-ventral axis
(Fig. 2A). In the gray matter adjacent to the lesion,
numerous ﬁbers and many neurons can be seen
(Fig. 2A). Heavily stained neurons with a large cell body
are concentrated in the adjacent ventral gray matter,
most of them are most likely corresponding to
motoneurons (Fig. 2A, arrowheads). Numerous large
caliber SMI-32 (+) ﬁbers grow into and are present in
the lesion site (Fig. 2B, black arrowheads), some ofwhich can unequivocally be recognized as motoneurons
axons, as they are prolongations of motoneuronal axon
bundles from the intact white matter (Fig. 2B, arrows).
Fig. 2C and D depicts a section from another animal
located at a more medial position than in the upper
panels of Fig. 2. In this section, the lesion occupies only
the ventral part of the spinal cord (Fig. 2C). Here too,
numerous SMI-32 (+) ﬁbers are found in the lesion
territory. In all animals, the ﬁber growth did not follow a
speciﬁc orientation (Fig. 2B, D) and only few exceptions
were observed to bridge the rostro-caudal extent of the
lesion (Fig. 2D, black arrowhead).Do CS ﬁbers contribute to the SMI-32 (+) ﬁbers
present in the lesion site?
To clarify whether CS ﬁbers are present and common
among the SMI-32 (+) ﬁbers detected in the lesion,
SMI-32-stained sections were compared to adjacent
Fig. 2. SMI-32-stained elements inside the lesion territory. (A) SMI-32-stained longitudinal section of the spinal cord at the level of the lesion. The
material originates from a monkey that received the control antibody (Mk-CH). The limits of the lesion are indicated by the blue-dashed lines and the
limits of the gray matter are shown with black-dotted lines. The lesion extends throughout the entire dorso-ventral axis. The large darkly stained
SMI-32 (+) neurons that accumulate in the ventral part of the gray matter are mostly motoneurons (white arrowheads). (B) Enlargement of the zone
marked by a rectangle in (A). Numerous SMI-32 (+) ﬁbers are visible in the lesion territory (arrowheads) and in the nearby intact white matter
(curved arrows). These last ﬁbers form a bundle of darkly stained ﬁbers running in a plane orthogonal to the axis of the spinal cord. Thus bundles are
typical of motoneurons axons crossing the white matter to exit the spinal cord and form ventral roots. Note that these ﬁbers do not change noticeably
their diameter as they cross the border between the intact tissue and the lesion. (C) SMI-32-stained longitudinal section of the spinal cord at the level
of the lesion. The material originates from a monkey that received the combination of the anti-Nogo-A antibody and BDNF (Mk-ABBo). The limits of
the lesion are indicated by the yellow-dashed line and the limits of the gray matter are shown with black-dotted lines. At this level, the lesion extends
only throughout the ventral portion of the spinal cord. (D) Enlargement of the zone marked by a rectangle in (C). Numerous SMI-32 (+) ﬁbers are
visible in the lesion site. Most ﬁbers grow erratically inside the lesion site, but a few ﬁbers may keep a ﬁxed orientation across the rostro-caudal
extent of the scar (black arrowhead). Drawings on far right represent the histological reconstructions of the lesions of the cervical cord on frontal
sections of the corresponding animals.
276 M.-L. Beaud et al. / Neuroscience 227 (2012) 271–282sections processed for BDA only, the tracer that was
injected before sacriﬁce of the animals into the primary
motor cortex. Numerous darkly BDA-stained CS ﬁbers
are visible in the dorsolateral funiculus rostrally to the
cervical lesion (Fig. 3B). Thus, the progression of the
CS ﬁbers is clearly stopped at the rostral border of
the lesion site (Fig. 3C). As described before, numerous
SMI-32 (+)-stained ﬁbers were seen in the lesion site
(Fig. 3D), particularly in its ventral portion (Fig. 3F). In
contrast, BDA (+)-stained ﬁbers were not found in the
corresponding regions of the adjacent BDA-processed
sections (Fig. 3E, G). These data show that the
overwhelming majority of the SMI-32 (+) ﬁbers
observed in the lesion territory do not comprise CS axons.What is the origin of the SMI-32 (+) ﬁbers visible in
the lesion site?
As described above, SMI-32 (+) motoneuronal axons are
sometimes clearly seen to penetrate in the scar tissue
(Fig. 2B) but the question remains as to whether other
ﬁber populations also signiﬁcantly contribute to the
population of SMI-32 densely labeled ﬁbers found in the
lesion territory. We measured the diameter of the SMI-32
(+) axons in the lesion site and compared it to that of
the SMI-32 (+) motoneuronal axons in the intact white
matter. Individual ﬁbers, analyzed either in the intact
white matter or in the lesion site (Fig. 2B), exhibited a
comparable diameter distribution independently of the
Fig. 3. The SMI-32-stained elements inside the scar tissue are not CS axons. (A) Reconstruction of the spinal lesion in monkey Mk-CGa, illustrating
the localization inside the spinal cord of the photomicrographs illustrated in panels (B)–(G). (B) Coronal section located immediately rostrally to the
spinal cord lesion stained for BDA and showing a large number of darkly stained CS tract ﬁbers in the dorsolateral funiculus. (C) Section stained for
BDA at the level of the dorsolateral funiculus. CS axons normally barely penetrate inside the lesion site. (D) In the lesion territory at the level of the
dorsal horn, few SMI-32 (+) ﬁbers can be seen. (E) Section adjacent to that depicted in (D) and stained for BDA. Note the absence of BDA (+)
ﬁbers in and outside of the lesion. (F) In the lesion territory at the level of the ventral horn, numerous SMI-32 (+) ﬁbers can be seen. (G)
Section adjacent to that depicted in (F) and stained for BDA. Note here also the absence of BDA (+) ﬁbers in and outside of the lesion site. In (C)–
(G) photomicrographs, the limits between the intact and the lesioned tissue are indicated by blue-dashed lines and the limits between the white and
the gray matter are shown with black-dotted lines. Scale bars = (B) 500 lm and (C–G) 250 lm.
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the diameter of motoneuronal axons did not change after
they crossed from the intact tissue into the lesion. In the
latter, both thick and thin SMI-32 (+) ﬁbers were found,however (Fig. 4A). The thick ﬁbers were usually heavily
stained with the SMI-32 antibody (Fig. 4A, white
arrowhead) and looked similar to motoneuronal axons in
the intact white matter. Other ﬁbers were rather thin and
Fig. 4. Distribution of the SMI-32-stained ﬁbers’ thickness in the lesion and in the intact white matter. (A) In the lesion territory, the diameter of SMI-
32 (+) ﬁbers diﬀers: some ﬁbers are rather thick and densely stained (white arrowhead) and some ﬁbers are rather thin and less densely stained
(black arrowhead). (B) Diameter distribution of the SMI-32 (+) ﬁbers observed inside the lesion site (yellow) and into the motoneuronal axons
bundles inside the intact white matter (gray) of one animal (Mk-ABS). Note that though largely overlapping, the comparison of both distributions
shows that motoneuronal axons are generally large and cannot account for all SMI-32 (+) ﬁbers found inside the lesion site. (C) Comparisons of the
SMI-32 (+) ﬁbers diameter distributions for nine animals (in the lesion site in color versus intact tissue in gray). The violin plots indicate the median
(white point), the ﬁrst and third quartiles (thicker line segment), the minimum and maximum of the data as well as the distribution of the observations
(envelope). A red segment line connects the median of the data obtained from one animal. Note that for all animals, the median diameter of ﬁbers
inside the lesion is always lower than the median diameter of motoneurons axons inside the intact white matter. A statistical comparison between
both ﬁbers’ populations conducted for each animal using the Student’s t-test indicated that the diﬀerence in diameter was statistically signiﬁcant for
all animals (p< 0.001).
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that are exceptional for motoneuronal axons inside the
intact white matter. For the monkey Mk-ABS, the
diameter distribution of the SMI-32 (+) ﬁbers in the scar
tissue was compared to that of the motoneuronal axons
outside the scar. Both distributions overlapped, but the
proportion of small diameter ﬁbers was higher in the
lesion site (Fig. 4B). This diﬀerence in ﬁber distribution
was consistently observed in all animals for which
diameter measurements were obtained (Fig. 4C; N= 9)
and was statistically signiﬁcant in all cases (Student’s
t-test, p< 0.01). The data thus suggest that
motoneuronal axons are not the only ﬁbers having the
capacity to invade the scar tissue.Do SMI-32 (+) ﬁbers present in the lesion territory
respond to the growth-promoting treatments?
To clarify whether the growth of SMI-32 (+) ﬁbers into the
lesion territory was aﬀected by the presence of the anti-
Nogo-A antibody, combined or not with BDNF, we
counted the number of SMI-32 (+) ﬁbers and measured
their cumulative length inside the lesion territory. The
number of SMI-32 (+) ﬁbers counted in the lesion site
varied considerably across the 18 animals (Fig. 5A) and
tended to increase in relation to the size of the lesion
(Fig. 5B). Comparing the group of animals that received
the control antibody to those that received the anti-
Nogo-A antibody using a multivariate nonparametric
analysis failed to show an inﬂuence of the treatment on
the growth of the ﬁbers in the scar (p> 0.05). Thesame was observed when comparing the group of
animals which received the control antibody to those
that received the combination of BDNF and the anti-
Nogo-A antibody.
SMI-32 (+) ﬁbers in the lesion territory belong
presumably mainly to motoneurons, but since the
thinner ﬁbers inside the lesion did not have counterparts
inside the motoneuronal axon bundles in the intact white
matter, these thin ﬁbers were probably not belonging to
motoneurons. By investigating separately the eﬀects of
the treatments on the largest and on the thinnest ﬁbers,
we tried to assess whether the treatments could have
acted diﬀerently on diﬀerent populations of neurons.
Considering the distribution of the ﬁbers’ thickness
(Fig. 4B, C), we arbitrarily chose the limit of 1.3 lm to
separate the entire population into a group of thin ﬁbers
that, presumably, were predominantly not motoneuronal
axons and a group of large ﬁbers for which the
proportion of motoneuronal axons is large. The
percentage of SMI-32 (+) ﬁbers having a diameter of
less than 1.3 lm was then plotted against the extent of
the hemi-cord lesion (Fig. 5C). As for the total number
of SMI-32 (+) ﬁbers (Fig. 5A), a large variability was
observed across animals and, here too, a multivariate
nonparametric analysis failed to disclose any eﬀect of
the treatments on these thin ﬁbers.
It was also conceivable that the SMI-32 (+) ﬁbers
increased in length, while their number remained
constant. The length of all ﬁber segments found in the
scar tissue was thus measured and summed into a
single cumulated value for each animal. Plotting the
Fig. 5. The number or cumulate length of SMI-32 (+) ﬁbers inside the lesion site are inﬂuenced neither by the anti-Nogo-A antibody nor applied
together with BDNF. (A) Bargraph representing the total number of SMI-32 (+) ﬁbers counted in the scar tissue for each animal and each treatment.
For all animals, the bar is divided in a lower region ﬁlled with a light color and corresponding to the ﬁbers with a diameter lower than 1.3 lm, and a
upper region ﬁlled with a darker color and corresponding to the larger ﬁbers (see text). Note that a large individual variability is present in all three
groups of animals and that the variability is equally important for the thin and the thick ﬁbers. No diﬀerence between treatment groups can be
detected. (B) Number of ﬁbers counted in the lesion site plotted as a function of the extent of the lesion and showing that this is not the sole result of
the lesion extent. No diﬀerence between treatment groups was detected. (C) Percentage of ﬁbers thinner than 1.3 lm counted in the lesion site
plotted as a function of the extent of the lesion and showing that for these ﬁbers too, the variability is not accounted for by the extent of the lesion and
that no diﬀerence between treatment groups was detected. (D) Number of ﬁbers counted in the lesion territory plotted as a function of their
cumulated length and showing that the growth of ﬁbers is not aﬀected by the treatments. Blue: control antibody-treated animals; red: anti-Nogo-A-
treated animals; yellow: anti-Nogo-A/BDNF-treated animals.
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relation to their cumulated length revealed a linear
relationship (Fig. 5D), which was conﬁrmed by high
coeﬃcients of correlation (r> 0.93) for each
experimental group considered separately, as well as for
all animals pooled together. In this situation too, the
multivariate nonparametric analysis did not disclose any
diﬀerence between the groups that could be related to
the treatments. Again, this tendency was independent
from the diameter of the ﬁbers. Thus, it appears that
neither the number nor the length of the SMI-32 (+)
ﬁbers observed in the scar tissue was inﬂuenced by the
anti-Nogo-A antibody alone or in combination with the
neurotrophic factor BDNF.DISCUSSION
We analyzed the lesion territory of 18 adult macaque
monkeys in the cervical spinal cord, 3.5–8.5 months
after a lateral hemisection lesion. Some of the animals
underwent growth and regeneration-promoting
treatments, i.e. intrathecal infusion of anti-Nogo-A
antibodies (for 1 month after the lesion) with or without
BDNF. Here we observed that a sizeable amount of
neurites was found in the lesion territory. The bulk of
these neurites presumably originated from motoneuronalaxons, but it is likely that axons of other origins, though
not of corticospinal neurons, also contributed to some
extent. The growth of these ﬁbers into the lesion site
was aﬀected neither by the presence of the anti-Nogo-A
antibody, nor by the presence of a mixture of this
antibody with BDNF.SMI-32-stained elements inside the spinal cord
The scar tissue formed after a spinal cord lesion is known
to hinder the growth of nerve ﬁbers into the lesion (Ramon
y Cajal, 1928; Brown and MacCouch, 1947; Clemente,
1955; Reier et al., 1983; Stichel and Muller, 1998;
Fawcett and Asher, 1999; Shearer and Fawcett, 2001;
Silver and Miller, 2004; Fawcett, 2006). In the present
study, 129–2539 SMI-32 (+) ﬁbers were found within
the lesion site of all the animals. Indirect evidence
suggests that a large proportion of these ﬁbers are
motoneuronal axons. First, in spinal cord sections,
strongly stained SMI-32 (+) neurons were, for a
majority, motoneurons; none of the SMI-32
(+)-descending or -ascending axons present in the
white matter showed such a darkly stained appearance.
Second, many of the strongly SMI-32 (+) ﬁbers in the
lesion exhibited a large diameter, characteristic of
motoneurons’ axons. Third, motoneuronal axons
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lesion could be seen. Nevertheless, axons of thinner
caliber were also present and probably represent non-
motoneuronal ﬁbers.
Comparisons between the SMI-32 (+) neurons and
those expressing choline acetyltransferase revealed that
82–100% of the positive neurons located in the ventral
horn of rats and primates (marmoset and rhesus
monkeys) were double-stained. However, the SMI-32
staining is not speciﬁc for motoneurons. It also stains,
though often less densely, neurons outside the ventral
horn, such as for instance neurons in the Clark’s
columns or in the intermediate cell column (Carriedo
et al., 1996; Tsang et al., 2000). Our observations are in
accordance with those reports. As shown in Figs. 1 and
2, the majority of the darkly SMI-32-stained neurons
was located in the motoneuronal pools of the ventral
horn. Other strongly SMI-32-stained neurons were
detected in positions corresponding to Rexed laminae
V–VIII, but they were clearly less numerous.
In the cat, intraspinal sprouting of motoneuron axons
was observed after root avulsions and spinal cord
injuries (Linda et al., 1985, 1992; Havton and Kellerth,
1987). Regeneration included the production of axon-
like processes from dendrites and that were called
‘‘dendraxons’’ (Linda et al., 1985, 1992; Havton and
Kellerth, 1987). These axons were myelinated, oriented
toward the ventral root fascicles and kept a constant
diameter. Although the existence of dendraxons has, at
least to the best of our knowledge, never been reported
in the primate, we cannot exclude that some of the SMI-
32 (+) ﬁbers observed here in the lesion site are
‘‘dendraxons’’.
CS ﬁbers fail to grow inside scar tissue
In a previous report on macaques that had been treated
with either a control antibody or the anti-Nogo-A
antibody during 1 month after injury, CS ﬁbers were only
exceptionally found to penetrate into the lesion site
(Freund et al., 2007). This observation is conﬁrmed here
in four additional animals receiving the control antibody
and in two animals treated with the anti-Nogo-A
antibody. We also show that, in ﬁve animals that
received a combination of the anti-Nogo-A antibody
together with BDNF, the number of ﬁbers’ numbers in
the lesion territory were not diﬀerent from those found in
the non-treated monkeys. In rodents, the absence of
axotomized CS ﬁbers in the lesion has repeatedly been
observed (Schnell and Schwab, 1990; Bregman et al.,
1995; Inman and Steward, 2003) and in primates
(Fouad et al., 2004; Freund et al., 2006). In these
species, while a treatment neutralizing Nogo-A often
leads to enhanced sprouting and regeneration of
axotomized CS ﬁbers, the ﬁbers grow around the lesion
instead of through the lesion. Interestingly, spontaneous
invasion of the lesion site occurs by dorsal root aﬀerents
like those containing the calcitonin gene-related peptide
(CGRP) or Substance P, and by serotoninergic-
descending ﬁbers which were reported to cross the
inhibitory boundary formed by reactive astrocytes and to
penetrate deeply into the scar (De Castro et al., 2005).In addition, neurites containing glycine and GABA were
also found within spinal scars (Brook et al., 1998).
Recently, it has been shown that the axons of adult
cat’s spinal commissural interneurons can
spontaneously grow through a local midline spinal
section in spite of the presence of CSPGs in the lesion
site and that these axons formed functional synaptic
connections with appropriate neural targets (Fenrich and
Rose, 2009). It thus appears that the mammalian spinal
scar tissue does not constitute an environment hostile to
regeneration for all ﬁber types. While this is ﬁrmly
established for rodents and cats (Matthews et al., 1979;
Linda et al., 1985, 1992; Havton and Kellerth, 1987;
Wallace et al., 1987; Wang et al., 1996; Brook et al.,
1998; Fenrich and Rose, 2009, 2011), it has, to our
knowledge, never been reported for adult macaque
monkeys. Our data show that SMI-32 (+) ﬁbers may
even be attracted by the scar tissue, to invade the
lesion site.Possible impact of the invasion of motoneuronal
neurites in the scar
Compared to the 400,000 axons in the corticospinal tract
of macaque monkeys, the relatively important number of
ﬁbers observed here in the lesion may have a positive
impact on supraspinal control of movement and
consequently on the functional recovery. Nevertheless,
their chaotic distribution in the spinal cord could impair
eﬃcient CS neurites to grow in the scar tissue and
rewire the motor centers to the motoneurons.
Confronting the present morphological data with the
percentage of functional recovery (Table 1), there was
no relationship between number of ﬁbers in the lesion
territory or their cumulative lengths and the functional
recovery.Anti-Nogo-A antibody treatment alone or combined
with BDNF does not induce detectable changes in the
number or growth of the SMI-32 (+) ﬁbers in the
lesion territory
The SMI-32 (+) ﬁbers encountered in the spinal lesion in
the present investigation demonstrate that this tissue is
growth permissive for some types of neuronal ﬁbers.
Nogo-A is not expressed in the scar tissue of rodents,
but it was of interest to ascertain whether or not an
antibody treatment neutralizing Nogo-A or an additional
delivery of BDNF would enhance the growth of SMI-32
(+) ﬁbers inside the lesion territory. However, we did
not detect any growth-promoting eﬀect of these
treatments on the SMI-32 (+) ﬁbers into the lesion site.
Finally, independent of the treatments and the thickness
of the ﬁbers, a great variability of the number and length
of the ﬁbers in the scar was observed across all
animals; local properties of the scar and its interface
with the surrounding gray and white matter tissue may
account for this variability, but the underlying molecular
mechanisms remained to be analyzed.
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